rocuronium bromide: clinical use

Prescribing considerations

• Administration requires immediate access to oxygenation, controlled ventilation, airway equipment and trained personnel.
• Ensure adequate anaesthesia or sedation and analgesia because rocuronium causes paralysis without unconsciousness or analgesia.
• Anticipate intubation difficulty and have an appropriate reversal and airway strategy.
• Correct significant electrolyte disturbance, altered blood pH and dehydration where possible.
• Effects may be prolonged in older people and in hepatic, biliary or renal impairment; responses may be markedly altered by neuromuscular disease, hypothermia, obesity or burns.
• Use caution with diagnosed or latent phaeochromocytoma because hypertensive crises have been reported.

Contraindications and cautions

• Hypersensitivity to rocuronium, bromide ions or any product excipient.

Monitoring

• Use quantitative or appropriate peripheral nerve stimulation to assess blockade and recovery.
• Monitor ventilation, oxygenation, cardiovascular observations and signs of anaphylaxis.
• Confirm adequate neuromuscular recovery before tracheal extubation.
• During intensive-care use, monitor for prolonged paralysis and skeletal muscle weakness, particularly with corticosteroids.

Clinical pharmacology

Rocuronium is a rapid-onset, intermediate-acting competitive antagonist at postsynaptic nicotinic acetylcholine receptors. It is eliminated through biliary and urinary routes; impaired organ function and critical illness can prolong recovery.

Formulation and product differences

• The selected products are ready-to-use intravenous solutions supplied in vial or ampoule presentations.
• Container type, excipient quantities, storage instructions and approved intensive-care wording can differ between products; consult the product-specific SmPC.
• Check compatibility before sharing an intravenous line because physical incompatibility is documented with several injectable medicines.

Injection

Route: Parenteral

Strengths: 10 mg/mL